Developing breakthrough medicines takes both courage and discipline. New treatments can transform patients’ lives, but the path to approval is rigorous and leaves little room for error.
Dr. Riad Sherif is the CEO of Oculis, a global biopharmaceutical company focused on breakthrough innovations in ophthalmology and neuro-ophthalmology. Oculis’ two late-stage clinical candidates, Privosegtor and Licaminlimab, present promising treatment options for those suffering from a broad range of neuro-ophthalmologic diseases and dry eye disease respectively.
In this episode, Dr. Sherif explains how Oculis identified significant unmet needs in eye care and set out to address them with an approach that departs from the traditional pharmaceutical model. He discusses the parallels between building a successful pharmaceutical company and running a successful public company, and looks ahead to a future with better treatment options for patients with optic neuritis and dry eye disease.
Highlights:
- Oculis’ origins: defining its place in the pharmaceutical landscape (3:01)
- What is neuroprotective therapy? (7:13)
- Privosegtor’s effects on optic neuritis (9:45)
- Neuroprotective therapy’s potential for treating multiple sclerosis (13:08)
- Trial progress for Privosegtor and Licaminlimab (15:26)
- The challenging realities of drug development (17:37)
- Why transparency and quality matter as a public company (21:18)
- Oculis’ go-to-market strategy (23:44)
- Defining success for the future of Oculis (27:27)
Links:
Feedback:
If you have questions about the show, or have a topic in mind you’d like discussed in future episodes, email our producer, [email protected].
Publisher: Source link
